<DOC>
	<DOCNO>NCT02659059</DOCNO>
	<brief_summary>The purpose part 1 study determine objective response rate ( ORR ) stage IV NSCLC subject treat nivolumab combination ipilimumab first line therapy . The purpose part 2 study compare overall survival Nivolumab ipilimumab combine short course chemotherapy standard care chemotherapy first line stage IV NSCLC .</brief_summary>
	<brief_title>Nivolumab Combination With Ipilimumab ( Part 1 ) ; Nivolumab Plus Ipilimumab Combination With Chemotherapy v . Chemotherapy Alone ( Part 2 ) First Line Therapy Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb ( BMS ) Clinical Trial participation , please visit www.BMSStudyConnect.com Men Women â‰¥ 18 year age Diagnosed stage IV NonSmall Cell Lung Cancer Diagnosed recurrent stage IIIB nonsmall cell lung cancer fail previous concurrent chemoradiation curative option . Subjects untreated CNS metastasis exclude . Subjects carcinomatous meningitis Subjects active , know suspected autoimmune disease . Subjects condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day first treatment . Women pregnant , plan become pregnant , and/or breastfeed study . Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>